Melasma is a common acquired disorder of symmetric facial hyperpigmentation, frequently linked to sun exposure and hormonal influences.
Why lasers and energy-based devices can trigger post-inflammatory hyperpigmentation, who is most at risk, and what the evidence supports to prevent and treat it.
What randomized trials and meta-analyses show about tranexamic acid for melasma, including efficacy by route (oral, topical, injected), safety, and who should avoid it.
How clinicians tell melasma, post-inflammatory hyperpigmentation, and solar lentigines apart, why it changes treatment and prognosis, and the evidence-based options for each.
Why visible light, not just UV, drives melasma and post-inflammatory pigmentation — and what tinted iron oxide sunscreens add to a summer skin care routine in 2026.
Evidence for FDA-approved hydroquinone + tretinoin + fluocinolone for melasma — efficacy vs monotherapy, adverse effects, and adjunctive options.